ABL Bio (Korea) Investor Sentiment

298380 Stock  KRW 27,050  600.00  2.17%   
About 62% of ABL Bio's investor base is looking to short. The analysis of current outlook of investing in ABL Bio suggests that many traders are alarmed regarding ABL Bio's prospects. The current market sentiment, together with ABL Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use ABL Bio stock news signals to limit their universe of possible portfolio assets.
  
few days ago at news.google.com         
Bio-related stocks, which have supported the KOSDAQ, are undergoing stock price adjustments due to u...
Google News at Macroaxis
over a month ago at news.google.com         
High Growth Tech Stocks in South Korea for October 2024 - Simply Wall St
Google News at Macroaxis
over two months ago at news.google.com         
ABL Bios decision to halt immunotherapy development leaves investors seeking answers - KBR
Google News at Macroaxis
over two months ago at news.google.com         
High Growth Tech Stocks In South Korea To Watch This August 2024 - Simply Wall St
Google News at Macroaxis
over two months ago at news.google.com         
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - StockTitan
Google News at Macroaxis
over three months ago at news.google.com         
Individual investors who hold 50 percent of ABL Bio Inc. gained 21, insiders profited as well - Simp...
Google News at Macroaxis
over three months ago at news.google.com         
SEHK Growth Companies With High Insider Ownership Showcasing Promising Futures - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Stud...
Google News at Macroaxis
over three months ago at news.google.com         
Is ABL Bio Using Too Much Debt - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Is ABL Bio Using Too Much Debt - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
PPF Group FDA granted full approval for Elahere for certain ovarian cancer patients - PPF Group
Google News at Macroaxis
over six months ago at news.google.com         
ABL Bio shareholders are up 12 percent this past week, but still in the red over the last five years...
Google News at Macroaxis
over six months ago at news.google.com         
ABL Bio shareholders are up 12 percent this past week, but still in the red over the last five years...
Google News at Macroaxis
over six months ago at news.google.com         
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates - Ma...
Google News at Macroaxis
over six months ago at news.google.com         
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates -
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about ABL Bio that are available to investors today. That information is available publicly through ABL media outlets and privately through word of mouth or via ABL internal channels. However, regardless of the origin, that massive amount of ABL data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ABL Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ABL Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ABL Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ABL Bio alpha.

ABL Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for ABL Stock analysis

When running ABL Bio's price analysis, check to measure ABL Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABL Bio is operating at the current time. Most of ABL Bio's value examination focuses on studying past and present price action to predict the probability of ABL Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABL Bio's price. Additionally, you may evaluate how the addition of ABL Bio to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk